Fluidx Medical Technology

Executive Summary

Fluidx Medical Technology is a privately held medical device company based in San Diego, California, pioneering next-generation embolic devices for vessel occlusion. Founded in 2015, the company focuses on developing the GPX Embolic Device, a novel platform designed to achieve deep, distal penetration in both peripheral and neurovascular applications. The device aims to address significant unmet needs in interventional oncology and hemorrhage control by offering superior control, durability, and ease of use compared to existing technologies. With a strong emphasis on procedural efficiency and patient outcomes, Fluidx is positioned to capture a meaningful share of the growing embolization market, which is driven by increasing adoption of minimally invasive procedures. As a private entity with no disclosed funding details or revenue, Fluidx operates in a competitive landscape with established players such as Boston Scientific and Medtronic. However, its differentiated technology and focus on challenging vascular anatomies could provide a strategic advantage. The company's next major milestones are expected to involve progressing the GPX device through clinical trials and securing regulatory clearances. Given the early stage and lack of public data, conviction in near-term commercial success is moderate, though the technology's potential to improve clinical outcomes warrants close monitoring.

Upcoming Catalysts (preview)

• H1 2027First-in-human clinical results for GPX Embolic Device60% success
• H2 2027Regulatory submission (510(k) or CE Mark) for peripheral vascular indication55% success
• H1 2027Series B or later-stage financing round70% success